Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Strong Initial Assay Results for its Fall 2024 Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Imaging Canada Liquidating Corp IMRSQ

IMRIS Inc designs, manufactures and markets Image-guided therapy systems that improves the effectiveness of therapy delivery. Its main product is the Visius surgical theater. The company provides its products to hospitals that deliver clinical services to patients in the neurosurgical, spinal, cerebrovascular and cardiovascular markets. The firm is focused on bringing enhanced visualization to the point of therapy delivery and is spread across Canada, United States, Europe and the Middle East and Asia-Pacific.


GREY:IMRSQ - Post by User

Imaging Canada Liquidating Corp
Bullboard Posts
User Avatar Image
(0)
•••
Comment by spring2010on Jul 27, 2010 6:33pm
229 Views
Post# 17301497

RE: Two Analysts’ ratings

RE: Two Analysts’ ratingsNo opinion but coverage also done by RBC Capital,Canaccord Adams, and Cormark Securities.  I picked up a position.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities